Oncology | Phase I/ Phase II Developments | UNITED KINGDOM

4D Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

4D Pharma Treats First Cancer Patients in Part B of Phase I/II trial of MRx0518 in Combination with Keytruda®

Lead Product(s): MRx0518,Pembrolizumab

Therapeutic Area: Oncology Product Name: MRx0518

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 06, 2020

Details:

Part B of the Phase I/II study will evaluate clinical benefit of MRx0518 and Keytruda®, defined as a complete response or partial response or stable disease for six months or longer.

Bicycle Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists

Lead Product(s): BT5528,Nivolumab

Therapeutic Area: Oncology Product Name: BT5528

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

New translational data for BT5528 and preclinical data for tumor-targeted immune cell agonists (TICAs™) will be presented during poster sessions at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22-24, 2020.

Autolus Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress

Lead Product(s): AUTO1

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 12, 2020

Details:

AUTO1 continued favorable safety profile and high level of clinical activity, pivotal Phase 1b/2 AUTO1-AL1 program in adult ALL initiated and enrolling patients.

4D Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

4D Hosts Virtual R&D Event Providing Updates on Clinical Programmes in Oncology and COVID-19

Lead Product(s): MRx0518,Pembrolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 05, 2020

Details:

Early data supports proof of concept in metastatic renal cell carcinoma, with potential to expand into additional tumour types.

Treos Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation

Lead Product(s): PolyPEPI1018

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 29, 2020

Details:

Treos plans to conduct a randomized Phase II study of PolyPEPI1018 in maintenance therapy setting for first-line treatment of MSS mCRC, as well as a Phase I/II study in late-stage patients as an add-on to third-line therapy.

Immunocore

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Immunocore Announces Dosing of First Patient with Fourth Immtac®

Lead Product(s): IMC-F106C

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 26, 2020

Details:

The trial (IMC-F106C-101) is designed to study the safety and preliminary activity of IMC-F106C as a monotherapy and in combination with a checkpoint inhibitor in patients with PRAME-expressing cancers.

Autolus Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program

Lead Product(s): AUTO3,Pembrolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

Oral presentation to highlight AUTO3 program, the Autolus's CAR T cell therapy being investigated in the Alexander study, a Phase 1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL).

Bicycle Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Bicycle Therapeutics to Present Trials in Progress Poster for BT5528 at the 2020 American Society of Clinical Oncology Virtual Meeting

Lead Product(s): BT5528,Nivolumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

Poster will highlight the design of the Bicycle's ongoing Phase I/II trial of BT5528 will be presented during an e-poster session at the American Society of Clinical Oncology (ASCO).

4D Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

4D Pharma Announces Successful Completion of Immuno-Oncology Study Safety Phase

Lead Product(s): MRx0518,Pembrolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 11, 2020

Details:

Part A of the study evaluated MRx0518 + pembrolizumab in patients with advanced solid tumors who had previously shown an initial clinical benefit to PD-1/PD-L1 immune checkpoint inhibitors.

Bicycle Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Bicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab

Lead Product(s): BT5528,Nivolumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

Details:

Bicycle Therapeutics dosed first patient in a Phase I dose escalation of BT5528 in combination with nivolumab. BT5528 is the Company’s first 2nd generation Bicycle® Toxin Conjugate and targets EphA2.

Find

Find Oncology Drugs in Phase I/II Clinical Development in UNITED KINGDOM

United Kingdom

Product Type

Companies

4D Pharma

4D Pharma Treats First Cancer Patients in Part B of Phase I/II trial of MRx0518 in Combination with Keytruda®

Bicycle Therapeutics

Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists

Autolus Therapeutics

Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress

4D Pharma

4D Hosts Virtual R&D Event Providing Updates on Clinical Programmes in Oncology and COVID-19

Treos Bio

Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation

Immunocore

Immunocore Announces Dosing of First Patient with Fourth Immtac®

Autolus Therapeutics

Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program

Bicycle Therapeutics

Bicycle Therapeutics to Present Trials in Progress Poster for BT5528 at the 2020 American Society of Clinical Oncology Virtual Meeting

4D Pharma

4D Pharma Announces Successful Completion of Immuno-Oncology Study Safety Phase

Bicycle Therapeutics

Bicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab